• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

国家经济和社会经济因素与糖尿病患者心血管疾病一级预防中危险因素控制的关系:来自 DISCOVER 研究的见解。

Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study.

机构信息

Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.

AstraZeneca, Gaithersburg, MD, USA.

出版信息

Indian Heart J. 2022 Sep-Oct;74(5):398-405. doi: 10.1016/j.ihj.2022.07.008. Epub 2022 Aug 2.

DOI:10.1016/j.ihj.2022.07.008
PMID:35926587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9647648/
Abstract

BACKGROUND

We sought to describe global patterns in achievement of risk factor control for primary prevention in patients with T2D and explore the association of country's GNI/capita with risk factor control.

METHODS

The DISCOVER study is a prospective, observational study of patients with T2D from 38 countries enrolled at initiation of second-line glucose-lowering therapy. We examined achievement of risk factor control (glycosylated hemoglobin <7%, blood pressure <140/90 mmHg, prescription of a statin) at 3 years among those without optimal control at baseline. Countries were stratified by gross national income (GNI)/capita, from 2017). We examined the impact of country GNI/capita with achievement of risk factor control.

FINDINGS

Our cohort included 9613 patients with T2D and without baseline cardiovascular disease (mean age 57.2 ± 8.7 years, 47.9% women). At baseline, 6354/7646 patients (83.1%) had suboptimal glucose control, 3449/9200 patients (37.5%) had suboptimal BP control, and 2800/4221 patients (66.7%) were not on an appropriate statin (sample sizes differed due to missing covariate data). Optimal control at 3 years of follow-up was achieved in 41% (glucose), 56% (blood pressure), and 29% (statins) of patients. There was significant variability in achievement of risk factor control across countries but no association between country GNI/capita with achievement of risk factor control (p > 0.08 for all).

INTERPRETATION

In a global, prospective study of patients with T2D, we found that cardiovascular risk factor control achievement was suboptimal despite 3 years of follow-up in specialized health care systems. Neither country-level nor patient-level socioeconomic factors fully explained this finding.

摘要

背景

我们旨在描述 T2D 患者一级预防中危险因素控制的全球模式,并探讨国家人均国民总收入(GNI)与危险因素控制的关系。

方法

DISCOVER 研究是一项前瞻性、观察性研究,纳入了来自 38 个国家的在开始二线降糖治疗时未达到最佳血糖控制的 T2D 患者。我们检查了在基线时未达到最佳控制的患者在 3 年内是否达到了危险因素控制(糖化血红蛋白<7%,血压<140/90mmHg,处方他汀类药物)。根据 2017 年的国民总收入(GNI)/人均收入,将国家分层。我们检查了国家 GNI/人均收入对危险因素控制的影响。

结果

我们的队列包括 9613 名无基线心血管疾病的 T2D 患者(平均年龄 57.2±8.7 岁,47.9%为女性)。基线时,6354/7646 例(83.1%)患者血糖控制不理想,3449/9200 例(37.5%)血压控制不理想,2800/4221 例(66.7%)未服用适当的他汀类药物(由于缺失协变量数据,样本量有所不同)。在 3 年的随访中,41%(血糖)、56%(血压)和 29%(他汀类药物)的患者达到了最佳控制。尽管在专业医疗保健系统中进行了 3 年的随访,但各国之间在实现危险因素控制方面存在显著差异,但国家 GNI/人均收入与危险因素控制之间无关联(所有结果 p>0.08)。

解释

在一项针对 T2D 患者的全球性、前瞻性研究中,我们发现,尽管在专业医疗保健系统中进行了 3 年的随访,但心血管危险因素控制的达标率仍不理想。国家层面和患者层面的社会经济因素都不能完全解释这一发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78d/9647648/4e78862cb7a4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78d/9647648/6cd75023ea8e/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78d/9647648/839e6414f4f2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78d/9647648/dd61b233c58e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78d/9647648/4e78862cb7a4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78d/9647648/6cd75023ea8e/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78d/9647648/839e6414f4f2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78d/9647648/dd61b233c58e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78d/9647648/4e78862cb7a4/gr3.jpg

相似文献

1
Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study.国家经济和社会经济因素与糖尿病患者心血管疾病一级预防中危险因素控制的关系:来自 DISCOVER 研究的见解。
Indian Heart J. 2022 Sep-Oct;74(5):398-405. doi: 10.1016/j.ihj.2022.07.008. Epub 2022 Aug 2.
2
Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.2型糖尿病患者综合心血管危险因素控制的全球模式:来自DISCOVER研究的见解
Diabetes Obes Metab. 2021 Jan;23(1):39-48. doi: 10.1111/dom.14180. Epub 2020 Sep 22.
3
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.改善他汀类药物治疗策略以降低 LDL 胆固醇:2 型糖尿病患者和非 2 型糖尿病患者达标相关因素。
Cardiovasc Diabetol. 2021 Jul 16;20(1):144. doi: 10.1186/s12933-021-01338-y.
4
Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus.他汀类药物一级预防中的依从性与 2 型糖尿病低危人群心血管风险和死亡的相关性。
J Am Heart Assoc. 2021 Jul 6;10(13):e020395. doi: 10.1161/JAHA.120.020395. Epub 2021 Jun 19.
5
Statins and diabetes: the good, the bad, and the unknown.他汀类药物与糖尿病:好坏参半,未知因素犹存。
Curr Atheroscler Rep. 2013 Feb;15(2):299. doi: 10.1007/s11883-012-0299-z.
6
Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk.他汀类药物一级预防与高血压高心血管风险患者的新发糖尿病。
Nutr Metab Cardiovasc Dis. 2013 Nov;23(11):1101-6. doi: 10.1016/j.numecd.2012.11.002. Epub 2013 Feb 15.
7
Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.他汀类药物用于高危老年患者的降脂治疗:治疗风险悖论。
JAMA. 2004 Apr 21;291(15):1864-70. doi: 10.1001/jama.291.15.1864.
8
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.在初级预防中,他汀类药物治疗的心血管获益和糖尿病风险:来自 JUPITER 试验的分析。
Lancet. 2012 Aug 11;380(9841):565-71. doi: 10.1016/S0140-6736(12)61190-8.
9
Smoking and cardiovascular disease in patients with type 2 diabetes: a prospective observational study.吸烟与 2 型糖尿病患者心血管疾病:一项前瞻性观察研究。
J Cardiovasc Med (Hagerstown). 2023 Nov 1;24(11):802-807. doi: 10.2459/JCM.0000000000001540. Epub 2023 Sep 27.
10
Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.他汀类药物用于心血管事件一级预防的使用模式:香港糖尿病患者的一项回顾性研究。
Am J Cardiovasc Drugs. 2008;8(3):199-205. doi: 10.2165/00129784-200808030-00006.

引用本文的文献

1
The triglyceride-glucose index is a promising predictor for the risk of cardiovascular disease in the diabetic population aged ≥60 years in the United States: a retrospective cohort study from NHANES (2007-2016).甘油三酯-葡萄糖指数是美国≥60岁糖尿病患者心血管疾病风险的一个有前景的预测指标:一项来自美国国家健康与营养检查调查(2007 - 2016年)的回顾性队列研究。
Front Endocrinol (Lausanne). 2025 Feb 21;16:1475590. doi: 10.3389/fendo.2025.1475590. eCollection 2025.

本文引用的文献

1
Comanagement of Risk Factors in Patients With Coronary Artery Disease: Insights From the APPEAR Study.冠心病患者危险因素的共管:来自 APPEAR 研究的见解。
J Am Heart Assoc. 2020 Jun 2;9(11):e015157. doi: 10.1161/JAHA.119.015157. Epub 2020 May 22.
2
A Community-Based Intervention for Managing Hypertension in Rural South Asia.基于社区的南亚农村地区高血压管理干预措施。
N Engl J Med. 2020 Feb 20;382(8):717-726. doi: 10.1056/NEJMoa1911965.
3
Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease.
糖化血红蛋白纵向值与多支冠状动脉疾病 2 型糖尿病患者心血管事件的相关性。
JAMA Netw Open. 2020 Jan 3;3(1):e1919666. doi: 10.1001/jamanetworkopen.2019.19666.
4
Performance of UK National Health Service compared with other high income countries: observational study.英国国民保健制度与其他高收入国家的表现比较:观察性研究。
BMJ. 2019 Nov 27;367:l6326. doi: 10.1136/bmj.l6326.
5
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南:通过血脂修饰降低心血管风险
Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31.
6
Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme.全球 2 型糖尿病的治疗和结局:DISCOVER 研究项目的简要回顾。
Diabetes Obes Metab. 2019 Nov;21(11):2349-2353. doi: 10.1111/dom.13817. Epub 2019 Jul 14.
7
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2019 ACC/AHA 心血管疾病一级预防指南:执行摘要:美国心脏病学会/美国心脏协会临床实践指南工作组的报告。
J Am Coll Cardiol. 2019 Sep 10;74(10):1376-1414. doi: 10.1016/j.jacc.2019.03.009. Epub 2019 Mar 17.
8
Association of Primary Care Physician Supply With Population Mortality in the United States, 2005-2015.2005-2015 年美国初级保健医生供给与人口死亡率的关系。
JAMA Intern Med. 2019 Apr 1;179(4):506-514. doi: 10.1001/jamainternmed.2018.7624.
9
Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.2型糖尿病患者及伴有风险的低密度脂蛋白胆固醇患者的降脂药物处方:一项基于瑞典国家糖尿病登记处的全国性指南依从性研究
BMC Health Serv Res. 2018 Nov 28;18(1):900. doi: 10.1186/s12913-018-3707-4.
10
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018 年美国心脏协会/美国心脏病学会/美国心血管血管外科学会/美国医师协会/美国心脏病学学院/美国糖尿病协会/美国老年学会/美国药学会/美国物理治疗协会/北美介入放射学会/国家脂质协会/美国预防、检测、评估与治疗高血压全国联合委员会临床实践指南:管理血胆固醇的系统评价。
J Am Coll Cardiol. 2019 Jun 25;73(24):3210-3227. doi: 10.1016/j.jacc.2018.11.004. Epub 2018 Nov 10.